Fagan, Anne M.

Sex-specific genetic predictors of Alzheimer’s disease biomarkers

(ADNI), A. D. N. I., Deming, Y., The Alzheimer Disease Genetics Consortium (ADGC), Dumitrescu, L., Barnes, L. L., Thambisetty, M., Kunkle, B., Gifford, K. A., Bush, W. S., Chibnik, L. B., et al. (2018) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 110

CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline

Suárez‐Calvet, M., Capell, A., Araque Caballero, M. Á., Morenas‐Rodríguez, E., Fellerer, K., Franzmeier, N., Kleinberger, G., Eren, E., Deming, Y., Piccio, L., et al. (2018) · EMBO Molecular Medicine

Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatments

Cited by 109

Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease

Vlassenko, A. G., McCue, L., Jasielec, M. S., Su, Y., Gordon, B. A., Xiong, C., Holtzman, D. M., Benzinger, T. L. S., Morris, J. C., & Fagan, A. M. (2016) · Annals of Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 106

Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non–Alzheimer Disease Pathophysiology

Gordon, B. A., Blazey, T., Su, Y., Fagan, A. M., Holtzman, D. M., Morris, J. C., & Benzinger, T. L. S. (2016) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 105

Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease

Schindler, S. E., Li, Y., Todd, K. W., Herries, E. M., Henson, R. L., Gray, J. D., Wang, G., Graham, D. L., Shaw, L. M., Trojanowski, J. Q., et al. (2019) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 101

NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers

Vos, S. J. B., Gordon, B. A., Su, Y., Visser, P. J., Holtzman, D. M., Morris, J. C., Fagan, A. M., & Benzinger, T. L. S. (2016) · Neurobiology of Aging

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 98

GPS driving: a digital biomarker for preclinical Alzheimer disease

Bayat, S., Babulal, G. M., Schindler, S. E., Fagan, A. M., Morris, J. C., Mihailidis, A., & Roe, C. M. (2021) · Alzheimer's Research & Therapy

Older Adults Driving StudiesDementia and Cognitive Impairment Research

Cited by 91

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease

Mattsson, N., Groot, C., Jansen, W. J., Landau, S. M., Villemagne, V. L., Engelborghs, S., Mintun, M. M., Lleo, A., Molinuevo, J. L., Jagust, W. J., et al. (2018) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 88

Extreme cerebrospinal fluid amyloid β levels identify family with late‐onset Alzheimer's disease presenilin 1 mutation

Kauwe, J. S. K., Jacquart, S., Chakraverty, S., Wang, J., Mayo, K., Fagan, A. M., Holtzman, D. M., Morris, J. C., & Goate, A. M. (2007) · Annals of Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 84

Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1polymorphisms

Wahrle, S. E., Shah, A. R., Fagan, A. M., Smemo, S., Kauwe, J. S., Grupe, A., Hinrichs, A., Mayo, K., Jiang, H., Thal, L. J., et al. (2007) · Molecular Neurodegeneration

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 84

Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer’s disease

Sung, Y. J., Yang, C., Norton, J., Johnson, M., Fagan, A., Bateman, R. J., Perrin, R. J., Morris, J. C., Farlow, M. R., Chhatwal, J. P., et al. (2023) · Science Translational Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 84

Phosphorylated Tau-Aβ42 Ratio as a Continuous Trait for Biomarker Discovery for Early-Stage Alzheimer’s Disease in Multiplex Immunoassay Panels of Cerebrospinal Fluid

Harari, O., Cruchaga, C., Kauwe, J. S. K., Ainscough, B. J., Bales, K., Pickering, E. H., Bertelsen, S., Fagan, A. M., Holtzman, D. M., Morris, J. C., et al. (2014) · Biological Psychiatry

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 82

Alzheimer’s disease risk variants show association with cerebrospinal fluid amyloid beta

Kauwe, J. S. K., Wang, J., Mayo, K., Morris, J. C., Fagan, A. M., Holtzman, D. M., & Goate, A. M. (2009) · neurogenetics

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 82

Concordance of Lumipulse cerebrospinal fluid t‐tau/Aβ42 ratio with amyloid PET status

Kaplow, J., Vandijck, M., Gray, J., Kanekiyo, M., Huyck, E., Traynham, C. J., Esquivel, R., Fagan, A. M., & Luthman, J. (2020) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 81

BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer’s disease

Lim, Y. Y., Hassenstab, J., Cruchaga, C., Goate, A., Fagan, A. M., Benzinger, T. L. S., Maruff, P., Snyder, P. J., Masters, C. L., Allegri, R., et al. (2016) · Brain

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 76

Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders

Gendron, T. F., Heckman, M. G., White, L. J., Veire, A. M., Pedraza, O., Burch, A. R., Bozoki, A. C., Dickerson, B. C., Domoto-Reilly, K., Foroud, T., et al. (2022) · Cell Reports Medicine

Dementia and Cognitive Impairment ResearchAmyotrophic Lateral Sclerosis Research

Cited by 70

Comparative analysis of Alzheimer's disease cerebrospinal fluid biomarkers measurement by multiplex SOMAscan platform and immunoassay‐based approach

Timsina, J., Gomez-Fonseca, D., Wang, L., Do, A., Western, D., Alvarez, I., Aguilar, M., Pastor, P., Henson, R. L., Herries, E., et al. (2022) · Journal of Alzheimer’s Disease

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 68

The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease

for the Dominantly Inherited Alzheimer Network (DIAN), Twohig, D., Rodriguez-Vieitez, E., Sando, S. B., Berge, G., Lauridsen, C., Møller, I., Grøntvedt, G. R., Bråthen, G., Patra, K., et al. (2018) · Acta Neuropathologica Communications

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 68

Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology

Morris, J. C., Weiner, M., Xiong, C., Beckett, L., Coble, D., Saito, N., Aisen, P. S., Allegri, R., Benzinger, T. L. S., Berman, S. B., et al. (2022) · Brain

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 68

Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease

Wang, Q., Wang, Y., Liu, J., Sutphen, C. L., Cruchaga, C., Blazey, T., Gordon, B. A., Su, Y., Chen, C., Shimony, J. S., et al. (2019) · NeuroImage: Clinical

Advanced Neuroimaging Techniques and ApplicationsDementia and Cognitive Impairment Research

Cited by 63

Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study

Boerwinkle, A. H., Gordon, B. A., Wisch, J., Flores, S., Henson, R. L., Butt, O. H., McKay, N., Chen, C. D., Benzinger, T. L. S., Fagan, A. M., et al. (2023) · The Lancet Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 55

Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study

Xiong, C., Jasielec, M. S., Weng, H., Fagan, A. M., Benzinger, T. L. S., Head, D., Hassenstab, J., Grant, E., Sutphen, C. L., Buckles, V., et al. (2016) · Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 54

ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-β pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis

Fagan, A. M., Christopher, E., Taylor, J. W., Parsadanian, M., Spinner, M., Watson, M., Fryer, J. D., Wahrle, S., Bales, K. R., Paul, S. M., et al. (2004) · The American Journal of Pathology

Alzheimer's disease research and treatmentsCholesterol and Lipid Metabolism

Cited by 54

Mendelian randomization and genetic colocalization infer the effects of the multi-tissue proteome on 211 complex disease-related phenotypes

Yang, C., Fagan, A. M., Perrin, R. J., Rhinn, H., Harari, O., & Cruchaga, C. (2022) · Genome Medicine

Genetic Associations and EpidemiologyBioinformatics and Genomic Networks

Cited by 53